Cancers can be treated in various ways depending on the type of cancer and how advanced the cancer is at diagnosis. Patients can be treated with a single treatment (monotherapy) or a combination of treatments. Common cancer treatments include surgery, chemotherapy, radiation, targeted therapy, hormonal therapy, and immunotherapy.
Stage IV melanoma carried a 24 month life expectancy three short years ago. That is what T.J. Sharpe’s first oncologist told him he was facing, after a visit to the ER for a fever turne...
ImmunoChemistry Technologies offers multiple tools for fluorescent imaging in the context of cancer research and oncology. ICT’s in vitro cell-based apoptosis assays allow biomedical re...
This is an exciting time for melanoma treatment, with a half-dozen new drugs approved in just over four years. This influx has brought a new complexity to the field, however, including questi...
While TDM is routinely used in a number of medical fields, it has not gained wide utilization in oncology. There is a growing body of evidence demonstrating that current dosing methods based...
Melanoma, a cancer of pigment-producing cells, accounts for nearly 200,000 new cases of cancer reported each year worldwide. It is the deadliest skin cancer. Alarmingly, in the U.S., the inci...
Precision medicine promises a more effective approach to disease treatment and management. It is based on analyzing mutations of disease samples to unlock mechanisms of disease development an...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
This presentation discusses the advantages and disadvantages of robotic surgery. The initial goals for a robotic prostatectomy will be discussed as well as patient expectations and outcomes.&...
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related mortality in the United States and worldwide. Current treatments are largely ineffective: single agent and combin...
The management of prostate cancer (PCa) continues to evolve and does so at a rapid rate. Research and technological developments continue to refine our definitions and management of this comp...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
LEARNING OBJECTIVES:1. Enhanced audience understanding regarding the controversy surrounding prostate cancer screening using the PSA blood test and use of the American Uro...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
In the case of Breast Cancer, the patient's cancer is usually detected by a mammogram or palpitation of an experienced Physician. However, these first indications that something is wrong must...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
I will discuss the use of genomic technologies - mostly ultrahigh-throughput DNA sequencing - to study normal human biology and to determine what goes wrong when we have disease. First I wil...
DATE: Tuesday, March 10, 2015 TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMTThe International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple...
Dr. Oliver Kepp will be presenting on:Immunogenic cell death fingerprinting utilizing a high-throughput screening approachThe strategy of immunogenic cell death fingerprinting has been design...
It has become widely accepted that the presence of intraepithelial CD8+ T cell correlate with improved patient survival. In contrast, tumors largely devoid of immune infiltrations or infiltra...
Female cancer patients in the reproductive years face a variety of diagnostic and therapeutic procedures which pose teratogenic hazards to an unexpected pregnancy. Ionizing radiation, diagnos...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Stage IV melanoma carried a 24 month life expectancy three short years ago. That is what T.J. Sharpe’s first oncologist told him he was facing, after a visit to the ER for a fever turne...
ImmunoChemistry Technologies offers multiple tools for fluorescent imaging in the context of cancer research and oncology. ICT’s in vitro cell-based apoptosis assays allow biomedical re...
This is an exciting time for melanoma treatment, with a half-dozen new drugs approved in just over four years. This influx has brought a new complexity to the field, however, including questi...
While TDM is routinely used in a number of medical fields, it has not gained wide utilization in oncology. There is a growing body of evidence demonstrating that current dosing methods based...
Melanoma, a cancer of pigment-producing cells, accounts for nearly 200,000 new cases of cancer reported each year worldwide. It is the deadliest skin cancer. Alarmingly, in the U.S., the inci...
Precision medicine promises a more effective approach to disease treatment and management. It is based on analyzing mutations of disease samples to unlock mechanisms of disease development an...
Biomarkers, with their associated “tsunami” of publications, represent what is arguably one of the largest areas of scientific inquiry in the history of biomedicine. Touted as the...
This presentation discusses the advantages and disadvantages of robotic surgery. The initial goals for a robotic prostatectomy will be discussed as well as patient expectations and outcomes.&...
Hepatocellular carcinoma (HCC) is a significant contributor to cancer-related mortality in the United States and worldwide. Current treatments are largely ineffective: single agent and combin...
The management of prostate cancer (PCa) continues to evolve and does so at a rapid rate. Research and technological developments continue to refine our definitions and management of this comp...
The burgeoning area of molecular risk assessment (gene expression profiling and/or proteomic tests) in the diagnosis and treatment of prostate cancer is rapidly illuminating how clinicians mi...
The landscape for treatment options in metastatic castration resistant prostate cancer has changed dramatically since 2010. There have been more therapies approved since 2010 than in the prio...
We have been developing methods to target drugs specifically to pathologic cells, thereby avoiding collateral toxicity to healthy cells. In the case of cancer, we have exploited up-regulation...
LEARNING OBJECTIVES:1. Enhanced audience understanding regarding the controversy surrounding prostate cancer screening using the PSA blood test and use of the American Uro...
DATE: September 9, 2015TIME: 9:00am PDT, 12:00PM EDTDriver mutations are causally implicated in tumorigenesis and disease progression, and they are defined by molecular abnormalities such as ...
In the case of Breast Cancer, the patient's cancer is usually detected by a mammogram or palpitation of an experienced Physician. However, these first indications that something is wrong must...
Matching the mutational profile of a patient's tumor with appropriate targeted agents is a goal of personalized medicine in oncology. The number of FDA-approved targeted therapies, as well as...
Germline cancer genetics became a reality with the cloning of the tumor suppressor gene RB1 for hereditary retinoblastoma in 1986 by Friend and Weinberg. The existence of cancer susceptibili...
I will discuss the use of genomic technologies - mostly ultrahigh-throughput DNA sequencing - to study normal human biology and to determine what goes wrong when we have disease. First I wil...
DATE: Tuesday, March 10, 2015 TIME: 09:00 PST, 11:00 CST, 12:00 EST, 16:00 GMTThe International Myeloma Working Group (IMWG) has issued updated criteria for the diagnosis of multiple...
Dr. Oliver Kepp will be presenting on:Immunogenic cell death fingerprinting utilizing a high-throughput screening approachThe strategy of immunogenic cell death fingerprinting has been design...
It has become widely accepted that the presence of intraepithelial CD8+ T cell correlate with improved patient survival. In contrast, tumors largely devoid of immune infiltrations or infiltra...
Female cancer patients in the reproductive years face a variety of diagnostic and therapeutic procedures which pose teratogenic hazards to an unexpected pregnancy. Ionizing radiation, diagnos...
Although the incidence of breast cancer is steadily increasing, mortality rates are decreasing. This means that the majority of women with breast cancer now survive, making it even more impor...
Follow
